Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a nutraceutical combination consisting of citicoline, creatine, and omega-3 fatty acids, developed by researchers at the University of Utah, including Dr. Deborah Yurgelun-Todd. The combination is designed to enhance cognitive function, specifically memory and attention, by targeting metabolic and bioenergetic pathways in the brain. Citicoline serves as a precursor for phospholipid synthesis and neurotransmitter production; creatine supports cellular energy homeostasis by maintaining ATP levels; and omega-3 fatty acids (typically EPA and DHA) are essential components of neuronal membranes with anti-inflammatory and neuroprotective properties. A clinical trial (NCT01502813) evaluated this specific formulation in healthy middle-aged women over a 28-day period, demonstrating potential benefits for neuropsychological measures of attention and memory.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citicoline + omega-3 fatty acids + creatine.